FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	S IN BENEFICIAL	OWNERSHIP

l	OMB APPE	ROVAL					
	OMB Number:	3235-0287					
Estimated average burden							
l	hours per response.	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Behbahani Ali</u>					2. Issuer Name and Ticker or Trading Symbol CRISPR Therapeutics AG [CRSP]						(Ch	telationship of the cell along the cell along the cell applications.	able)	g Pers	on(s) to Issu	
(Last) (First) (Middle) 1954 GREENSPRING DRIVE SUITE 600				3. Date of Earliest Transaction (Month/Day/Year) 06/11/2019							Officer below)	(give title		Other (s _i below)	pecify	
(Street) TIMONI (City)	UM M		21093 (Zip)	4. 1	f Ame	endment, C	Date (of Original File	ed (Month/Da	ay/Year)	Line	X Form fi	led by One	Repo	(Check App rting Person One Report	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date			Transaction te onth/Day/Ye	Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) 5)			Beneficia	s ally ollowing	Form:	Direct Conditions of the condi	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
							Code V	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)			(11150.4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	Code (Transaction of Expiration Da Code (Instr. Derivative (Month/Day/Y		te of Securities		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$43.52	06/11/2019		A		15,000		(1)	06/11/2029	Common Stock	15,000	\$0.00	15,000)	D	

Explanation of Responses:

1. This option was granted on June 11, 2019 with respect to 15,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2019; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2020 Annual General Meeting of Shareholders.

Remarks:

/s/ Sasha Keough, attorney-in-

<u>fact</u>

** Signature of Reporting Person

Date

06/13/2019

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.